It has been demonstrated that susceptibility to palbociclib treatment in breast cancer may be predicted by immunohistochemical identification of Thr172-phosphorylated CDK4 (an activating phosphorylation performed through the CDK-activating kinase, CAK). This evidence concerns the gene CDK7 and breast cancer.